Clinical trial costs

By Dr. Matthew Watson

Based on a survey* of 21 drug makers, 12 biotechs, nine device makers and 23 contract research organizations, PharmaLot has recently published the following metrics for current clinical trial costs (see full article here)

Average per-patient trial costs across all therapeutic areas:

Phase I: $21,883

Phase II: $36,070

Phase IIIa: $47,523

Phase IIIb: $47,095

Phase IV: $17,042

Average cost per patient for a cardiovascular trial:

Phase II: $33,700

Phase IIIa: $21,750

Phase IIIb: $6,830

In oncology, the average per patient trial cost:

Phase II: $73,303

Phase IIIa: $57,207

Phase IIIb: $65,900

For central nervous system disorders:

Phase II: $28,197

Phase IIIa: $33,768

Phase IIIb: $41,824

For diabetes:

Phase II: $ 8,854

Phase IIIa: $12,667

Phase IIIb: $10,700

Anyone have any thoughts or data as to how this compares to cell therapy trials?

--Lee

*survey conducted by Cutting Edge Information.

http://www.celltherapyblog.com hosted by http://www.celltherapygroup.com

Related Post

• Commercialization of Regenerative Medicine: Learning from Spin-Outs - April 28th, 2013
• 2013 Annual Regenerative Medicine Industry Report - April 21st, 2013
• Cell Therapy Blog welcomes 2013 - January 6th, 2013
• The Accuracy of Adipose Stem Cell Doses - December 23rd, 2012
• A proposed 6-step platform for the cell therapy industry to consider in combating non-compliant cell therapy treatments - December 16th, 2012
• The ROI on pant-wearing and other social media tips - December 16th, 2012
• Six steps to fighting non-compliant cell therapy treatments. --- The stuff of grey shades, spades, ivory towers and (ahem) balls. - December 2nd, 2012
• Cell Therapy Industry Group Welcomes its 4,000th member - November 11th, 2012
• GEN's "Cellular Therapy Wave Finally Cresting". An overview and data set. - November 4th, 2012
• CIRM addresses some tough questions. Is it all just glass towers and basic research? - October 21st, 2012
• Cell therapy portfolio outperforms major indices year-to-date - October 14th, 2012
• The cost of clinical trial data bias/loss, FDA's new job and the need for bold leadership. - September 30th, 2012
• Anticipated short-term cell therapy industry clinical milestones - September 30th, 2012
• Two lessons I learned this week. - September 16th, 2012
• Are some cell counts too good to be true? Why some companies' product data may mislead. - September 2nd, 2012
• Is the cell therapy sector outperforming the major indices? - August 12th, 2012
• FDA 1. RSI 0. Regenerative Sciences (Regenexx) vs FDA (2012) - July 29th, 2012
• Bioreactor Design and Bioprocess Controls for Industrialized Cell Processing - June 17th, 2012
• Industry-sponsored cardiovascular cell therapies. Some metrics. - May 27th, 2012
• Cell-based Cancer Immunotherapies. Some metrics.. - May 20th, 2012
• Another > $100M month for companies in the cell therapy space - May 6th, 2012
• Predicting the Success of the Late-Stage Cell-Based Cancer Immunotherapy Pipeline? - March 11th, 2012
• 2011 EMA Committee for Advanced Therapies (CAT) classification record. What can be learned? - January 1st, 2012
• Inactive and recently failed or terminated phase III or II/III cell therapy trials - December 18th, 2011
• Recently approved cell therapy products - December 18th, 2011
• Active phase III or II/III cell therapy trials - December 11th, 2011
• Sabrina Cohen Foundation Thanks Stem Cell Researchers - November 27th, 2011
• Commercializing Cell-based Regenerative Medicines - November 13th, 2011
• Cell Therapy & Regenerative Medicine Domains Available - September 25th, 2011
• Commercial-stage Cell Therapy Companies and Products - September 18th, 2011
• Potential far-reaching implications of the ongoing fight over point-of-care autologous cell therapy - September 18th, 2011
• Good Data? $100. Good Product Development? $100. Good Commercialization Strategy? Priceless. - August 14th, 2011
• Cell Therapy's Got Talent Technology Showcase - A Call for Cell Therapy Manufacturing Technology Presentations - July 10th, 2011
• In vivo cell trafficking just took a leap forward - July 3rd, 2011
• Cell Therapies: Commercializing a New Class of Biopharmaceuticals - February 12th, 2011
• The LinkedIn Cell Therapy Industry Group - 1,000 members strong - January 15th, 2011
• Careers in cell therapy & regenerative medicine - October 11th, 2010
• FDA files injunction again Regenerative Sciences citing Regenexx violates regulations - August 12th, 2010
• The changing face of PR and why it matters to regenmed - June 12th, 2010
• Biotech tax credit appears perfectly designed for cell therapy companies to recoup research dollars spent in 2009-10 - May 22nd, 2010
• Google to Invest in Regenerative Medicine - May 5th, 2010
• Latest Cell Therapy Approval by FDA. Dendreon's Provenge. - April 30th, 2010
• Stem cells for a Webby! - April 28th, 2010

Regenerative Medicine Comments Off on Clinical trial costs | July 31st, 2011

About... Dr. Matthew Watson

Categories

• Bone Marrow Stem Cells (2,936)
• Cardiac Stem Cells (1,265)
• Global News Feed (3,255)
• Integrative Medicine (105)
• IPS Cell Therapy (460)
• Nano medicine (2)
• Regenerative Medicine (44)
• Skin Stem Cells (2,195)
• Spinal Cord Stem Cells (948)
• Stem Cell Therapy (528)

Archives

Recommended Sites

• California Stem Cell Research
• Cord Blood Banking
• Gene Therapy Breakthroughs
• Immortality Medicine
• Medical School Review
• Nano Technology American Physicians
• Videos Of Stem Cell Therapy